secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030662
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M
--------------------------------------------------------------------------------

- Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.
- Fifth consecutive quarter of positive Adjusted EBITDA: $0.5M vs $0.1M in prior year quarter.
- Launched SimpliGraft and SimpliMax amniotic membrane allografts; added 15 new distributors and 20 IDN contracts in Q2.
- Entered $5.0M private placement at $0.64/share on August 7, 2024; cash $5.4M at June 30, 2024.
- Reaffirms FY2024 revenue guidance $116M-$120M (27%-31% annual growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/0001493152-24-030662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer